Kisspeptin-54
The full-length 54-amino-acid form of kisspeptin — the master regulator of reproductive hormones. More potent and longer-acting than Kisspeptin-10. Being studied for fertility treatment, low testosterone diagnosis, and reproductive disorders. May offer a more natural approach to stimulating reproductive hormone production than GnRH or HCG.
Dosage
Research only — 1-10 nmol/kg IV or subcutaneous
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Administration

Shop Research-Grade Peptides
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Reproductive Axis Stimulation
Full-length form with greater receptor affinity than kisspeptin-10.
IVF Potential
May replace HCG trigger with lower OHSS risk in fertility protocols.
Mechanism of Action
Kisspeptin-54 is the full-length bioactive form of kisspeptin, cleaved from the 145-amino-acid precursor protein encoded by the KISS1 gene. It binds to KISS1R (GPR54) on GnRH neurons in the hypothalamic arcuate and anteroventral periventricular nuclei with the same binding site as KissPeptin-10 but with greater receptor affinity and a longer duration of action due to its extended peptide chain providing additional receptor contacts.
KISS1R is a Gq/11-coupled GPCR that activates phospholipase C upon kisspeptin binding, generating IP3 and DAG. IP3-mediated calcium release and DAG-activated PKC depolarize GnRH neurons, triggering robust GnRH pulse secretion into the hypophyseal portal blood supply. This GnRH pulse then stimulates anterior pituitary gonadotrophs to release both LH and FSH. The 54-amino-acid form produces a more sustained and robust GnRH/LH response compared to KissPeptin-10, attributed to its longer receptor occupancy time and potentially slower dissociation kinetics.
In clinical research, kisspeptin-54 has shown particular promise in reproductive medicine. A single bolus injection can trigger an LH surge sufficient for oocyte maturation in IVF protocols — potentially replacing the traditional HCG trigger with lower risk of ovarian hyperstimulation syndrome (OHSS), because kisspeptin's effect is physiological (triggering endogenous GnRH and LH) rather than pharmacological (directly mimicking LH like HCG). In functional hypothalamic amenorrhea (where stress or low body weight suppresses the reproductive axis), kisspeptin-54 infusion can restore LH pulsatility, confirming that the GnRH neurons remain responsive and the defect lies upstream at the kisspeptin level. The longer half-life of kisspeptin-54 compared to kisspeptin-10 (due to greater resistance to matrix metalloproteinases that degrade kisspeptins) makes it more practical for clinical applications where sustained receptor activation is desired.
Regulatory Status
Not FDA approved. Active clinical trials for IVF protocols and functional hypogonadism (Imperial College London, Harvard). Potential to replace hCG as an oocyte maturation trigger in IVF.
Risks & Safety
Common
hot flashes, abdominal discomfort, headache, facial flushing.
Serious
may desensitize reproductive hormones with continuous or excessive use, unpredictable reproductive hormone fluctuations.
Rare
severe hot flashes, allergic reactions.
Compare Kisspeptin-54 With
Research Papers
30Published: January 21, 2026
AI Summary
An intravenous kisspeptin bolus did not change vasopressin levels in healthy adults, so it does not appear useful as a provocative test for vasopressin deficiency. The lack of effect may be due to dose, route, or species differences.
Published: December 24, 2025
AI Summary
Lower KISS1 in decidual cells was linked to cesarean scar pregnancy, and restoring KISS1 increased cell invasion and migration via the PI3K/AKT pathway. The work suggests KISS1 helps balance trophoblast–decidua interactions and may be relevant to scar pregnancy.
Published: October 7, 2025
AI Summary
Kisspeptin-10 reduced triple-negative breast cancer cell growth and migration, reactivated KISS1, reversed EMT, and promoted apoptosis. The findings support exploring kisspeptin-10 as a treatment for this aggressive breast cancer subtype.
Published: December 18, 2025
AI Summary
Kisspeptin-54 reduced chondrocyte aging in osteoarthritis by protecting telomeres via SIRT3 and limiting p53 acetylation. The findings suggest kisspeptin-54 could help slow cartilage breakdown in OA.
Published: November 10, 2025
AI Summary
Serum and seminal kisspeptin were compared between fertile and infertile men with abnormal semen. The work aims to determine whether kisspeptin can serve as a biomarker for male infertility.
Published: January 23, 2026
AI Summary
Kisspeptin levels and gene variants were examined in women with PCOS, given its role in reproductive hormone regulation. Prior studies have been inconsistent, and this work aims to clarify the relationship.
Published: July 14, 2025
AI Summary
First-trimester serum kisspeptin was evaluated as a predictor of pregnancy complications. The work aims to determine whether this biomarker can identify women at higher risk early in pregnancy.
Published: September 23, 2025
AI Summary
Kisspeptin slowed growth of pterygium cells by blocking chemokine ligands in the microenvironment. The findings may support new biomarkers and treatments for this common eye condition.
Published: June 15, 2025
AI Summary
Kisspeptin improved myasthenia gravis in a mouse model by rebalancing Th1, Th17, and Treg cells and inhibiting NF-kappaB. The results suggest kisspeptin may influence autoimmune disease through neuroendocrine–immune crosstalk.
Published: June 24, 2025
AI Summary
Kisspeptin-54 reduced stroke damage in mice by restoring the blood-brain barrier via GATA-4 and occludin, cutting infarct size and improving neurological function. The KISS1/GPR54 pathway may be a therapeutic target for ischemic stroke.
Published: July 27, 2025
AI Summary
Kisspeptin affects cancer cell migration and controls the reproductive axis. The review summarizes current knowledge on its physiology and potential clinical uses.
Published: May 19, 2025
AI Summary
The kisspeptin receptor system is involved in reproduction, cancer, diabetes, and heart disease. The article reviews methods for finding agonists and antagonists and discusses challenges and future directions for drug development.
Published: May 4, 2025
AI Summary
Placentas from COVID-19 pregnancies in South Africa had higher kisspeptin expression and more inflammation and vascular problems. The findings support ongoing monitoring of mothers and babies after COVID-19 during pregnancy.
Published: May 10, 2025
AI Summary
Intranasal kisspeptin quickly raised gonadotropin levels in humans, offering a non-invasive way to stimulate reproductive hormones. The approach could improve patient acceptance for treating reproductive disorders.
Published: November 4, 2025
AI Summary
Kisspeptin activates reproductive hormones and brain regions involved in sexual and emotional processing, making it a candidate for treating low sexual desire. Better delivery methods and understanding of sex-specific effects are needed before clinical use.
Published: October 15, 2025
AI Summary
Kisspeptin increased reproductive hormones in humans but did not change anxiety levels. The results clarify that kisspeptin's clinical potential lies in reproductive and psychosexual disorders rather than anxiety.
Published: May 14, 2025
AI Summary
PFAS exposure was linked to metabolic biomarkers in Spanish adolescents, with kisspeptin possibly involved. The work explores how these chemicals may disrupt the endocrine–metabolic axis.
Published: March 2, 2025
AI Summary
Intravenous kisspeptin increased oxytocin levels in healthy adults, with a stronger effect in women. The results support kisspeptin as a possible provocative test for oxytocin deficiency.
Published: December 10, 2025
AI Summary
Serum kisspeptin, NKB, and GABA were altered in Chinese women with PCOS and linked to hormone profiles. The work explores whether these markers could help characterize or diagnose PCOS.
Published: March 4, 2025
AI Summary
Infertile men with low sperm count had lower kisspeptin and free testosterone and higher LH and FSH. A KISS1 gene variant was more common in infertile men, suggesting kisspeptin may be a marker for male reproductive health.
Published: May 18, 2025
AI Summary
Kisspeptin regulates reproductive behavior and emotional state through brain regions beyond the hypothalamus. The evidence supports exploring kisspeptin-based therapies for reproductive and psychosexual disorders.
Published: June 24, 2025
AI Summary
Kisspeptin, originally identified as a metastasis suppressor, is now known as a key regulator of puberty and GnRH release. The chapter discusses its distribution and role in reproduction across rodents, fish, and birds.
Published: July 7, 2025
AI Summary
Kisspeptin stimulates GnRH release and is central to puberty, adult reproduction, and reproductive aging in female mammals. The chapter reviews its role in controlling the hypothalamic–pituitary–gonadal axis and its therapeutic potential.
Published: March 25, 2025
AI Summary
GnRH injection was tested for its effect on kisspeptin levels in girls with suspected precocious puberty. The pilot study explores whether GnRH suppresses kisspeptin via negative feedback and how kisspeptin relates to other pubertal hormones.
Published: February 9, 2025
AI Summary
Liposomes coated with a kisspeptin analog targeted breast cancer cells via GPR54 and improved doxorubicin delivery, extending survival in tumor-bearing mice. The approach could offer a new way to target breast cancer with chemotherapy.
Published: October 31, 2025
AI Summary
Early puberty in patients with primary adrenal insufficiency due to MC2R mutations was evaluated. The work explores how the melanocortin system and leptin influence GnRH neurons and pubertal timing.
Published: March 16, 2025
AI Summary
Genetic causes of central precocious puberty were analyzed in 90 patients, including MKRN3, DLK1, KISS1, KISS1R, and MECP2. The study provides a molecular and clinical overview of CPP in this cohort.
Published: October 30, 2024
AI Summary
Chronic nasal kisspeptin-54 improved mood-related symptoms in rats with Parkinson's disease, partly through amygdaloid GABA. The findings suggest kisspeptin could help address depression and anxiety in Parkinson's.
Published: July 28, 2024
AI Summary
Kisspeptin-10 and its analogs reduced cervical cancer cell growth and migration by modulating kinase signaling. The analogs bound the kisspeptin receptor and showed promise as potential therapeutic agents for cervical cancer.
Published: September 9, 2024
AI Summary
A meta-analysis examined FTO and KISS1 gene variants and their link to PCOS in Asian populations. The work aims to clarify whether these polymorphisms increase PCOS risk.
Frequently Asked Questions
What is Kisspeptin-54?
The full-length 54-amino-acid form of kisspeptin — the master regulator of reproductive hormones. More potent and longer-acting than Kisspeptin-10. Being studied for fertility treatment, low testosterone diagnosis, and reproductive disorders. May offer a more natural approach to stimulating reproductive hormone production than GnRH or HCG.
What is Kisspeptin-54 used for?
The full-length 54-amino-acid form of kisspeptin — the master regulator of reproductive hormones. More potent and longer-acting than Kisspeptin-10. Being studied for fertility treatment, low testosterone diagnosis, and reproductive disorders. May offer a more natural approach to stimulating reproductive hormone production than GnRH or HCG.
What is the dosage for Kisspeptin-54?
Clinical research: 1-10 nmol/kg IV or subcutaneous. Fertility protocols: single bolus or pulsatile infusion. No established commercial dosing protocol.
What are the side effects of Kisspeptin-54?
Common: hot flashes, abdominal discomfort, headache, facial flushing. Serious: may desensitize reproductive hormones with continuous or excessive use, unpredictable reproductive hormone fluctuations. Rare: severe hot flashes, allergic reactions.
How does Kisspeptin-54 work?
Kisspeptin-54 is the full-length bioactive form of kisspeptin, cleaved from the 145-amino-acid precursor protein encoded by the KISS1 gene. It binds to KISS1R (GPR54) on GnRH neurons in the hypothalamic arcuate and anteroventral periventricular nuclei with the same binding site as KissPeptin-10 but with greater receptor affinity and a longer duration of action due to its extended peptide chain providing additional receptor contacts. KISS1R is a Gq/11-coupled GPCR that activates phospholipase C upon kisspeptin binding, generating IP3 and DAG. IP3-mediated calcium release and DAG-activated PKC depolarize GnRH neurons, triggering robust GnRH pulse secretion into the hypophyseal portal blood supply. This GnRH pulse then stimulates anterior pituitary gonadotrophs to release both LH and FSH. The 54-amino-acid form produces a more sustained and robust GnRH/LH response compared to KissPeptin-10, attributed to its longer receptor occupancy time and potentially slower dissociation kinetics. In clinical research, kisspeptin-54 has shown particular promise in reproductive medicine. A single bolus injection can trigger an LH surge sufficient for oocyte maturation in IVF protocols — potentially replacing the traditional HCG trigger with lower risk of ovarian hyperstimulation syndrome (OHSS), because kisspeptin's effect is physiological (triggering endogenous GnRH and LH) rather than pharmacological (directly mimicking LH like HCG). In functional hypothalamic amenorrhea (where stress or low body weight suppresses the reproductive axis), kisspeptin-54 infusion can restore LH pulsatility, confirming that the GnRH neurons remain responsive and the defect lies upstream at the kisspeptin level. The longer half-life of kisspeptin-54 compared to kisspeptin-10 (due to greater resistance to matrix metalloproteinases that degrade kisspeptins) makes it more practical for clinical applications where sustained receptor activation is desired.
How is Kisspeptin-54 administered?
Kisspeptin-54 is administered via intravenous or subcutaneous injection.
What is the half-life of Kisspeptin-54?
The half-life of Kisspeptin-54 is 28 minutes (IV); longer subcutaneously.
Is Kisspeptin-54 legal?
Not FDA approved. Active clinical trials for IVF protocols and functional hypogonadism (Imperial College London, Harvard). Potential to replace hCG as an oocyte maturation trigger in IVF.
Related Peptides
5-Amino-1MQ
A pill that aims to switch fat cells from 'storage mode' to 'burning mode' by blocking an enzyme (NNMT) that is overactive in the fat tissue of overweight people. Not technically a peptide, but commonly sold alongside them. Unlike appetite suppressants, this targets the fat cells directly rather than making you eat less. The science is promising in lab studies, but there are no completed human trials yet.
AICAR
A natural compound that activates your cells' energy sensor — the same pathway that turns on during exercise. Mimics the metabolic effects of endurance exercise at the cellular level, helping with fat burning, glucose uptake, and building more mitochondria. Banned by WADA as a metabolic modulator after detection in professional cycling.
Alprostadil
A medication that treats erectile dysfunction by relaxing the blood vessels in the penis, allowing blood to flow in and create an erection. Unlike pills that require arousal to work, this works directly at the injection or application site — you don't need to be in the mood. Available as an injection into the penis or as a small pellet inserted into the urethra.
Enclomiphene
A medication that boosts natural testosterone production by blocking estrogen's feedback signal in the brain. Used in men's health clinics as an alternative to testosterone shots that preserves fertility and testicular function. Unlike mixed clomiphene (Clomid), enclomiphene lacks the estrogen-like component (zuclomiphene) that causes many of clomiphene's side effects.